282 related articles for article (PubMed ID: 37524790)
1. SF3B1 hotspot mutations confer sensitivity to PARP inhibition by eliciting a defective replication stress response.
Bland P; Saville H; Wai PT; Curnow L; Muirhead G; Nieminuszczy J; Ravindran N; John MB; Hedayat S; Barker HE; Wright J; Yu L; Mavrommati I; Read A; Peck B; Allen M; Gazinska P; Pemberton HN; Gulati A; Nash S; Noor F; Guppy N; Roxanis I; Pratt G; Oldreive C; Stankovic T; Barlow S; Kalirai H; Coupland SE; Broderick R; Alsafadi S; Houy A; Stern MH; Pettit S; Choudhary JS; Haider S; Niedzwiedz W; Lord CJ; Natrajan R
Nat Genet; 2023 Aug; 55(8):1311-1323. PubMed ID: 37524790
[TBL] [Abstract][Full Text] [Related]
2. Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors.
Lappin KM; Barros EM; Jhujh SS; Irwin GW; McMillan H; Liberante FG; Latimer C; La Bonte MJ; Mills KI; Harkin DP; Stewart GS; Savage KI
Cancer Res; 2022 Mar; 82(5):819-830. PubMed ID: 35027467
[TBL] [Abstract][Full Text] [Related]
3. Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in
Kim H; George E; Ragland R; Rafail S; Zhang R; Krepler C; Morgan M; Herlyn M; Brown E; Simpkins F
Clin Cancer Res; 2017 Jun; 23(12):3097-3108. PubMed ID: 27993965
[No Abstract] [Full Text] [Related]
4. PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
Gralewska P; Gajek A; Marczak A; Mikuła M; Ostrowski J; Śliwińska A; Rogalska A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33352723
[TBL] [Abstract][Full Text] [Related]
5. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.
Haynes B; Murai J; Lee JM
Cancer Treat Rev; 2018 Dec; 71():1-7. PubMed ID: 30269007
[TBL] [Abstract][Full Text] [Related]
6. Olaparib-Resistant
Biegała Ł; Gajek A; Marczak A; Rogalska A
Cells; 2023 Mar; 12(7):. PubMed ID: 37048111
[TBL] [Abstract][Full Text] [Related]
7. ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.
Yazinski SA; Comaills V; Buisson R; Genois MM; Nguyen HD; Ho CK; Todorova Kwan T; Morris R; Lauffer S; Nussenzweig A; Ramaswamy S; Benes CH; Haber DA; Maheswaran S; Birrer MJ; Zou L
Genes Dev; 2017 Feb; 31(3):318-332. PubMed ID: 28242626
[TBL] [Abstract][Full Text] [Related]
8. Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent.
Sizemore ST; Mohammad R; Sizemore GM; Nowsheen S; Yu H; Ostrowski MC; Chakravarti A; Xia F
Mol Cancer Res; 2018 Jul; 16(7):1092-1102. PubMed ID: 29592899
[TBL] [Abstract][Full Text] [Related]
9. The Influence of PARP, ATR, CHK1 Inhibitors on Premature Mitotic Entry and Genomic Instability in High-Grade Serous
Gralewska P; Gajek A; Rybaczek D; Marczak A; Rogalska A
Cells; 2022 Jun; 11(12):. PubMed ID: 35741017
[TBL] [Abstract][Full Text] [Related]
10. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K
Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466
[TBL] [Abstract][Full Text] [Related]
11. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
[No Abstract] [Full Text] [Related]
12. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
[TBL] [Abstract][Full Text] [Related]
13. Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps.
Paes Dias M; Tripathi V; van der Heijden I; Cong K; Manolika EM; Bhin J; Gogola E; Galanos P; Annunziato S; Lieftink C; Andújar-Sánchez M; Chakrabarty S; Smith GCM; van de Ven M; Beijersbergen RL; Bartkova J; Rottenberg S; Cantor S; Bartek J; Ray Chaudhuri A; Jonkers J
Mol Cell; 2021 Nov; 81(22):4692-4708.e9. PubMed ID: 34555355
[TBL] [Abstract][Full Text] [Related]
14. PARPi focus the spotlight on replication fork protection in cancer.
Schlacher K
Nat Cell Biol; 2017 Oct; 19(11):1309-1310. PubMed ID: 29087384
[TBL] [Abstract][Full Text] [Related]
15. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
[TBL] [Abstract][Full Text] [Related]
16. R-Loop Accumulation in Spliceosome Mutant Leukemias Confers Sensitivity to PARP1 Inhibition by Triggering Transcription-Replication Conflicts.
Liu ZS; Sinha S; Bannister M; Song A; Arriaga-Gomez E; McKeeken AJ; Bonner EA; Hanson BK; Sarchi M; Takashima K; Zong D; Corral VM; Nguyen E; Yoo J; Chiraphapphaiboon W; Leibson C; McMahon MC; Rai S; Swisher EM; Sachs Z; Chatla S; Stirewalt DL; Deeg HJ; Skorski T; Papapetrou EP; Walter MJ; Graubert TA; Doulatov S; Lee SC; Nguyen HD
Cancer Res; 2024 Feb; 84(4):577-597. PubMed ID: 37967363
[TBL] [Abstract][Full Text] [Related]
17. Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance.
Kim DS; Camacho CV; Kraus WL
Exp Mol Med; 2021 Jan; 53(1):42-51. PubMed ID: 33487630
[TBL] [Abstract][Full Text] [Related]
18. BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency.
Sun C; Yin J; Fang Y; Chen J; Jeong KJ; Chen X; Vellano CP; Ju Z; Zhao W; Zhang D; Lu Y; Meric-Bernstam F; Yap TA; Hattersley M; O'Connor MJ; Chen H; Fawell S; Lin SY; Peng G; Mills GB
Cancer Cell; 2018 Mar; 33(3):401-416.e8. PubMed ID: 29533782
[TBL] [Abstract][Full Text] [Related]
19. Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models.
Kim H; Xu H; George E; Hallberg D; Kumar S; Jagannathan V; Medvedev S; Kinose Y; Devins K; Verma P; Ly K; Wang Y; Greenberg RA; Schwartz L; Johnson N; Scharpf RB; Mills GB; Zhang R; Velculescu VE; Brown EJ; Simpkins F
Nat Commun; 2020 Jul; 11(1):3726. PubMed ID: 32709856
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of poly(ADP-ribose) polymerase induces synthetic lethality in BRIP1 deficient ovarian epithelial cells.
Ciccone MA; Adams CL; Bowen C; Thakur T; Ricker C; Culver JO; Maoz A; Melas M; Idos GE; Jeyasekharan AD; Matsuo K; Roman LD; Gruber SB; McDonnell KJ
Gynecol Oncol; 2020 Dec; 159(3):869-876. PubMed ID: 33032822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
